Courtney, R.

docetaxel patient -014813 su -014813 cycle study cancer dose level treatment combination level phase neutropenia pharmacokinetic 75 mg /m grade sunitinib neutropenic fever fatigue anti-tumour activity toxicity day 1 agent diarrhoea growth activity 3 patients fl uid pressure trial tumour table plasma factor response fever anti-tumour disease european hypertension grade 4 neutropenia 3–4 journal m om el t m el p 7 days inhibition tumours 1–2 neutropenic melanoma dosing cl /f inhibitor receptor fi rst oncol response rate kinase 4 patients auc 24 therapy concentration cytotoxic tyrosine p fizer trial p fizer inc p fizer employee vz /f phase ii studies dose intensity cancer 4 7 om m el prostate cancer disease stabilisation vz /f n hair discolouration cycle 1 bene fit rate p fizer grade 3 fatigue